Iridex (IRIX) Short term Debt (2020 - 2021)

Name: Iridex (IRIX) Short term Debt (2020 - 2021) | Business Quant
Creator: Business Quant

Iridex's quarterly Short term Debt came in at $2.2 million in Q2 2021, up 74.94% quarter-over-quarter from $1.2 million in Q1 2021.

Iridex has reported Short term Debt for 2 years, with the latest figure at $2.2 million in Q2 2021.

For the quarter ending Q2 2021, Short term Debt changed N/A year-over-year to $2.2 million; the trailing twelve-month figure through Apr 2021 stood at $2.2 million (changed N/A YoY), and the FY2021 full-year result was $1.2 million, changed N/A from the prior year.
Short term Debt for Q2 2021 stood at $2.2 million, up from $1.2 million in the prior quarter.
The five-year high for Short term Debt was $2.2 million in Q2 2021, with the low at $1.2 million in Q1 2021.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	152.82 Bn	146.17 Bn	6.27 Bn
2	Stryker	115.07 Bn	112.19 Bn	3.81 Bn
3	Medtronic	95.25 Bn	87.08 Bn	5.76 Bn
4	Boston Scientific	71.38 Bn	70.17 Bn	3.61 Bn
5	Edwards Lifesciences	51.08 Bn	47.41 Bn	1.29 Bn
6	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn
7	Dexcom	28.84 Bn	27.72 Bn	750.30 Mn
8	GE HealthCare Technologies	28.56 Bn	26.49 Bn	1.98 Bn
9	Steris	20.71 Bn	20.30 Bn	697.10 Mn
10	Iridex	18.87 Mn	14.27 Mn	4.74 Mn

Download Data 🔒